Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: ArtAlley who wrote (84123)	2/23/2000 1:29:00 PM
From: Jenna	Read Replies (1) \| Respond to of 120523

Now here are 'analyzed' stocks that appeared before: CIMA, and MATX.. CIMA is a second timer and earnings play reporting Thursday but its not the earnings but rather the closeness CIMA is approaching profitability... Its expecting only to lose -0.01 cents and has lots of analyst appeal. CIMA LABS INC. Announces Approval of DuraSolv(TM) Patent DuraSolv(TM) is CIMA's Second Fast-Dissolve Technology; CIMA is the Only Oral Drug Delivery Company With Multiple Fast-Dissolve Technologies EDEN PRAIRIE, Minn., Feb. 23 /PRNewswire/ -- CIMA LABS INC. (Nasdaq: CIMA - news) today announced the issuance of its DuraSolv(TM) patent (U.S. Patent No. 6,024,981) from the U.S. Patent and Trademark Office. ''This confirms our commitment to fast-dissolve technology and our efforts to protect CIMA's technology,'' commented John M. Siebert, Ph.D., President and Chief Executive Officer of CIMA LABS INC. ''CIMA is the only oral drug delivery company with multiple fast-dissolve technologies. We offer our partners a platform of fast-dissolve solutions that have long-term patent protection.'' MATX also a third timer.. it is constantly reaching new 52 week high upon high. MATXMatrix CEO Presents at BIO CEO & Investor Conference; Company Plans NDA Filing By Year-end FREMONT, Calif., Feb. 15 /PRNewswire/ -- Matrix Pharmaceutical, Inc. (Nasdaq: MATX - news) plans to file a New Drug Application (NDA) with the Food & Drug Administration (FDA) for IntraDose® Injectable Gel (cisplatin/epinephrine) by year's end, according to CEO Michael Casey. Casey made the statement in a presentation today in New York at the 2nd Annual BIO CEO & Investor Conference. Casey also presented company highlights for 1999, saying that Matrix experienced significant progress in the past 12 months. ''Fast-track'' designation for its lead product, IntraDose, topped the year's achievements. MATX just presented at a special biotechnology investor conference organized by the industry for its peers and investors. Some of the company presentations include: Matrix Pharmaceutical Inc. (NASDAQ: MATX);....